METROPOLIS HEALTHCARE Q2 FY27 CONCALL: EXPECTS 16% REVENUE GROWTH TREND TO CONTINUE IN H2 FY27, TARGETS 27–28% MEDIUM-TERM EBITDA MARGINS; PLANS B2C PRICE HIKE BY EARLY 2027 & AIMS TO INCREASE CENTER-TO-LAB RATIO TO 30:1 BY FY27-END